Skip to content
★ Sign in to follow
AP

Angiotech Pharmaceuticals Inc Stock: price and insider trades · United States

US·Mcap US$541.5M

No insider purchase over the last 90 days. The latest, by Gross Jeffrey M, was filed 26 Mar 2010.

Angiotech Pharmaceuticals Inc: what insiders have been doing

Every trade that managers of Angiotech Pharmaceuticals Inc disclose to SEC (Form 4) is tracked on this page. Nothing new has been filed by managers of Angiotech Pharmaceuticals Inc in twelve months, the latest record being from 25 June 2012.

Over the whole record (from 2008), the tally stands at 240 purchases and 7 sales.

Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Insider Decl.
308
Thresholds
n/a
Buy Volume
€3M
240 ops. · all time
Sell Volume
€14M
7 ops. · all time
Fundamental score
Ranked 254 of 26,912 companies
87.9
score / 100
Value
92
Quality
84
FCF yld11%
Earn yld22%
EV/EBITDA3.4x
ROE50%
Gross mgn39%
Net mgn33%
Debt/EBITDA0.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$3.63
Analyst consensus
·
Income statement
RevenueUS$359.8M
Gross profitUS$141.5M39% margin
EBITDAUS$174.3M48% margin
Net incomeUS$118.2M26.5% margin
Valuation
PER (trailing)4.1x
P/Book1.8x
Beta1.93
Balance sheet & cash
Market capUS$541.5M
Total debtUS$45.1M
Free Cash FlowUS$59M
Debt / Equity10%
Profitability & ownership
ROE49.9%
ROA23.6%
% insiders61.0%
% institutions10.3%
Last declaration on 25 June 2012
Declarations308 total
  • ▼
    Related company / holdingExecutives
    17M USD0SEC
    1,115,000 shares@ US$15.43Common SharesSEC:0001209191-12-035281:0
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    9,000 shares0Common StockSEC:0001096481-11-000019:0
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    6,000 shares0Common StockSEC:0001096481-11-000019:1
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    1,500 shares0Common StockSEC:0001096481-11-000019:2
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    2,000 shares0Common StockSEC:0001096481-11-000019:3
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    20,000 shares0Common StockSEC:0001096481-11-000019:4
  • ●
    SVP, Research & DevelopmentExecutives
    0SEC
    12,500 shares0Common StockSEC:0001096481-11-000019:5
  • ●
    SVP, LegalExecutives
    0SEC
    2,000 shares0Common StockSEC:0001096481-11-000013:0
  • ●
    SVP, LegalExecutives
    0SEC
    800 shares0Common StockSEC:0001096481-11-000013:1
  • ●
    SVP, Sales & MarketingExecutives
    0SEC
    70,700 shares0Common StockSEC:0001096481-11-000016:0
  • ●
    CEO & PresidentExecutives
    0SEC
    435,356 shares0Common StockSEC:0001096481-11-000012:0
  • ●
    CEO & PresidentExecutives
    0SEC
    375,000 shares0Common StockSEC:0001096481-11-000012:1
  • ●
    CEO & PresidentExecutives
    0SEC
    102,000 shares0Common StockSEC:0001096481-11-000012:2
  • ●
    CEO & PresidentExecutives
    0SEC
    3,332,616 shares0Common StockSEC:0001096481-11-000012:3
  • ●
    CEO & PresidentExecutives
    0SEC
    567,595 shares0Common StockSEC:0001096481-11-000012:4
  • ●
    CEO & PresidentExecutives
    0SEC
    156,933 shares0Common StockSEC:0001096481-11-000012:5
  • ●
    CEO & PresidentExecutives
    0SEC
    33,000 shares0Common StockSEC:0001096481-11-000012:6
  • ●
    CEO & PresidentExecutives
    0SEC
    89,692 shares0Common StockSEC:0001096481-11-000012:7
  • ●
    CEO & PresidentExecutives
    0SEC
    40,848 shares0Common StockSEC:0001096481-11-000012:8
  • ●
    CEO & PresidentExecutives
    0SEC
    53,000 shares0Common StockSEC:0001096481-11-000012:9
  • ●
    CEO & PresidentExecutives
    0SEC
    30,500 shares0Common StockSEC:0001096481-11-000012:10
  • ●
    CEO & PresidentExecutives
    0SEC
    476,813 shares0Common StockSEC:0001096481-11-000012:11
  • ●
    CEO & PresidentExecutives
    0SEC
    157,738 shares0Common StockSEC:0001096481-11-000012:12
  • ●
    CEO & PresidentExecutives
    0SEC
    47,000 shares0Common StockSEC:0001096481-11-000012:13
  • ●
    CEO & PresidentExecutives
    0SEC
    15,600 shares0Common StockSEC:0001096481-11-000012:14

25 of 308 declarations

About Angiotech Pharmaceuticals Inc

Angiotech Pharmaceuticals Inc is a company focused on the development of pharmaceutical products and medical devices. It primarily concentrates on treatments related to vascular diseases and cancers.